BAL
MCID: ACT216
MIFTS: 35

Acute Leukemia of Ambiguous Lineage (BAL)

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Leukemia of Ambiguous Lineage

MalaCards integrated aliases for Acute Leukemia of Ambiguous Lineage:

Name: Acute Leukemia of Ambiguous Lineage 53 6 38
Mixed Phenotype Acute Leukemia 53 72
Acute Biphenotypic Leukemia 53 72
Acute Leukemia of Indeterminate Lineage 53
Acute Leukemia of Undetermined Lineage 53
Undifferentiated Acute Leukemia 53
Acute Undifferentiated Leukemia 72
Mixed Lineage Acute Leukemia 53
Biphenotypic Acute Leukaemia 29
Biphenotypic Acute Leukemia 53
Aml with Lymphoid Markers 53
All with Myeloid Markers 53
Hybrid Acute Leukemia 53
Bal 53

Classifications:



External Ids:

UMLS 72 C0023464 C0280141 C2826025

Summaries for Acute Leukemia of Ambiguous Lineage

MalaCards based summary : Acute Leukemia of Ambiguous Lineage, also known as mixed phenotype acute leukemia, is related to leukemia, acute myeloid and idiopathic acute eosinophilic pneumonia. An important gene associated with Acute Leukemia of Ambiguous Lineage is VHL (Von Hippel-Lindau Tumor Suppressor). The drugs Cytarabine and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and t cells.

Related Diseases for Acute Leukemia of Ambiguous Lineage

Diseases related to Acute Leukemia of Ambiguous Lineage via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 12.0
2 idiopathic acute eosinophilic pneumonia 11.3
3 sarcoidosis 1 10.7
4 lung disease 10.7
5 acute leukemia 10.7
6 idiopathic interstitial pneumonia 10.6
7 pulmonary fibrosis 10.6
8 pulmonary fibrosis, idiopathic 10.5
9 leukemia 10.5
10 dermatitis 10.5
11 pulmonary sarcoidosis 10.5
12 extrinsic allergic alveolitis 10.5
13 mercury poisoning 10.5
14 bronchiolitis 10.4
15 pneumonia 10.4
16 wilson disease 10.4
17 bronchiolitis obliterans 10.4
18 interstitial lung disease 10.4
19 cytokine deficiency 10.4
20 lymphocytic leukemia 10.3
21 myeloid leukemia 10.3
22 bronchitis 10.3
23 balo concentric sclerosis 10.3
24 leukemia, acute lymphoblastic 10.3
25 hematopoietic stem cell transplantation 10.3
26 essential thrombocythemia 10.3
27 asbestosis 10.3
28 allergic hypersensitivity disease 10.3
29 pulmonary tuberculosis 10.3
30 encephalopathy 10.3
31 asbestos intoxication 10.3
32 fibrosis of extraocular muscles, congenital, 1 10.2
33 cryptogenic organizing pneumonia 10.2
34 respiratory failure 10.2
35 eosinophilic pneumonia 10.2
36 cystic fibrosis 10.2
37 invasive aspergillosis 10.2
38 vascular disease 10.2
39 encephalitis 10.2
40 hypereosinophilic syndrome 10.2
41 graft-versus-host disease 10.2
42 leukemia, acute lymphoblastic 3 10.2
43 precursor t-cell acute lymphoblastic leukemia 10.2
44 leukemia, chronic myeloid 10.2
45 acute promyelocytic leukemia 10.2
46 lymphoblastic lymphoma 10.2
47 asthma 10.2
48 porphyria 10.2
49 bacterial pneumonia 10.2
50 proteasome-associated autoinflammatory syndrome 1 10.1

Graphical network of the top 20 diseases related to Acute Leukemia of Ambiguous Lineage:



Diseases related to Acute Leukemia of Ambiguous Lineage

Symptoms & Phenotypes for Acute Leukemia of Ambiguous Lineage

Drugs & Therapeutics for Acute Leukemia of Ambiguous Lineage

Drugs for Acute Leukemia of Ambiguous Lineage (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
2
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
5
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
8
Morphine Approved, Investigational Phase 3 57-27-2 5288826
9
Dalteparin Approved Phase 3 9005-49-6
10
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
13
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
15
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
16
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
17
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
18
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
19
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
20
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Mercaptopurine Approved Phase 3 50-44-2 667490
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
27
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
28
Thioguanine Approved Phase 3 154-42-7 2723601
29
Daunorubicin Approved Phase 3 20830-81-3 30323
30
Ichthammol Approved Phase 3 8029-68-3
31
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
32
Pegaspargase Approved, Investigational Phase 3 130167-69-0
33
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
34
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
35
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
36
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
37 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
38
Cortisone Experimental Phase 3 53-06-5 222786
39
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
40 Antiviral Agents Phase 3
41 Anti-Bacterial Agents Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Topoisomerase Inhibitors Phase 3
44 Antidotes Phase 3
45
asparaginase Phase 3
46 Calcium, Dietary Phase 3
47 Anesthetics, Dissociative Phase 3
48 Neurotransmitter Agents Phase 3
49 Analgesics Phase 3
50 Cola Phase 3

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
3 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
4 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
5 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
6 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
7 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
8 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
11 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
12 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
16 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Not yet recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Leucovorin;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine;Vincristine Sulfate
17 T-cell Depletion In Unrelated Donor Marrow Transplantation Withdrawn NCT00006451 Phase 3 anti-thymocyte globulin;cyclophosphamide;cyclosporine;methotrexate;methylprednisolone
18 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
19 An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia Completed NCT02399917 Phase 2 Azacitidine
20 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
21 Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Completed NCT00003960 Phase 2 busulfan;cyclophosphamide;methylprednisolone
22 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY Completed NCT00732316 Phase 2
23 Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
24 A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
25 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
26 A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation Completed NCT00003913 Phase 2 busulfan;cyclophosphamide;methylprednisolone
27 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
28 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
29 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia Completed NCT00990249 Phase 2 Busulfan;Clofarabine;Thymoglobulin
30 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
31 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
32 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
33 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
34 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
35 Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
36 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
37 A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) Completed NCT00061945 Phase 1, Phase 2 allopurinol;cyclophosphamide;daunorubicin hydrochloride;vincristine sulfate;dexamethasone;asparaginase;imatinib mesylate;methotrexate;cytarabine;trimethoprim-sulfamethoxazole;mercaptopurine;leucovorin calcium;acyclovir
38 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
39 Induction Intensification in Infant ALL: A Children's Oncology Group Study Completed NCT00002756 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
40 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
41 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
42 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
43 A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Recruiting NCT02135874 Phase 2 Clofarabine;Cytarabine;Dexamethasone;Idarubicin;Sorafenib Tosylate;Vincristine Sulfate
44 Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study Recruiting NCT03012672 Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
45 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement Recruiting NCT02828358 Phase 2 Azacitidine;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
46 A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Recruiting NCT03128034 Phase 1, Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
47 A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Recruiting NCT03267186 Phase 2 Ibrutinib
48 Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML Recruiting NCT02115295 Phase 2 Cladribine;Cytarabine;Gilteritinib;Idarubicin;Midostaurin;Venetoclax
49 Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen Recruiting NCT00719888 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine;Mycophenolate Mofetil;Thiotepa
50 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Recruiting NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus;Fludarabine

Search NIH Clinical Center for Acute Leukemia of Ambiguous Lineage

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia of Ambiguous Lineage cell therapies at LifeMap Discovery.

Genetic Tests for Acute Leukemia of Ambiguous Lineage

Genetic tests related to Acute Leukemia of Ambiguous Lineage:

# Genetic test Affiliating Genes
1 Biphenotypic Acute Leukaemia 29

Anatomical Context for Acute Leukemia of Ambiguous Lineage

MalaCards organs/tissues related to Acute Leukemia of Ambiguous Lineage:

41
Myeloid, Bone, T Cells, Bone Marrow, Liver, Testes, B Lymphoblasts

Publications for Acute Leukemia of Ambiguous Lineage

Articles related to Acute Leukemia of Ambiguous Lineage:

(show top 50) (show all 181)
# Title Authors PMID Year
1
Acute Leukemias of Ambiguous Lineage: Clarification on Lineage Specificity. 38
31352981 2019
2
Genetic Testing in the Diagnosis and Biology of Acute Leukemia. 38
31367767 2019
3
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. 38
30707502 2019
4
Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia. 38
31388256 2019
5
Multiparameter Flow Cytometry Applications in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL). 38
31321906 2019
6
Acute leukemia in a patient with 15q overgrowth syndrome. 38
30861314 2019
7
Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. 38
30578714 2019
8
Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. 38
30769192 2019
9
Early Deaths in Pediatric Acute Leukemia: A Major Challenge in Developing Countries. 38
30615014 2019
10
Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. 38
31033213 2019
11
Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. 38
30514800 2019
12
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. 38
30786841 2019
13
Xiao W, Bharadwaj M, Levine M, et al. PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood Adv. 2018;2(23):3526-3539. 38
30926597 2019
14
Patient with mixed-phenotype acute leukemia with CBFB rearrangement. 38
31012358 2019
15
18F-FDG PET/CT for extramedullary relapse of acute leukemia of ambiguous lineage. 38
30967343 2019
16
[Clinical Characteristics of Patients with Ph+ Mixed Phenotype Acute Leukemia]. 38
30998137 2019
17
Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged. 38
30872272 2019
18
Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome. 38
30956966 2019
19
T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with NOTCH1 mutation as a good prognostic factor. 38
31118806 2019
20
Mixed Phenotype Acute Leukemia, B/Myeloid with t(9;22): Diagnostic and Therapeutic Challenges. 38
30828170 2019
21
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. 38
30328137 2019
22
Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation. 38
30614203 2019
23
Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions. 38
30255571 2019
24
CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. 38
31141090 2019
25
Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case. 38
30203419 2018
26
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. 38
30530780 2018
27
Mixed-phenotype acute leukemia characteristics: first report from Iran. 38
30019150 2018
28
Rapid diagnosis of mixed phenotype acute leukemia after identifying a blood histogram abnormality. 38
30009244 2018
29
Mixed-phenotype acute leukemia, T/megakaryoblastic. 38
30498070 2018
30
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. 38
30117174 2018
31
Diagnostic challenges in T-lymphoblastic lymphoma, early T-cell precursor acute lymphoblastic leukemia or mixed phenotype acute leukemia: A case report. 38
30313079 2018
32
Philadelphia-positive mixed phenotype acute leukemia presenting with PML-RARα fusion transcript without t(15;17) on cytogenetic studies. 38
30310796 2018
33
[Haploid hematopoietic stem cell transplantation in the treatment of Ph chromosome positive mixed phenotype acute leukemia: report of two cases with literature review]. 38
30369192 2018
34
Cytoplasmic CD3 expression in infant acute megakaryoblastic leukemia: A new ambiguous lineage subtype? 38
29935384 2018
35
[The 464th case: sudden convulsion and coma in a patient with acute leukemia]. 38
29996279 2018
36
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. 38
29991687 2018
37
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. 38
29449681 2018
38
Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. 38
29550836 2018
39
An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL). 38
29546454 2018
40
Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia. 38
28882084 2018
41
The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified. 38
29269643 2018
42
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. 38
29620650 2018
43
Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. 38
29492206 2018
44
Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival. 38
29223952 2018
45
[Successful treatment with rituximab in acute disseminated encephalomyelitis with whole spinal cord involvement following HLA haploidentical transplantation]. 38
30626794 2018
46
[Successful treatment of secondary graft failure in a mixed-phenotype acute leukemia patient with haploidentical hematopoietic stem cell transplantation and post-transplant cyclophosphamide administration]. 38
29877234 2018
47
Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. 38
30140473 2018
48
Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. 38
29112013 2018
49
Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia. 38
29892548 2018
50
[Initial presentation of lymphoblastic crisis in a pediatric chronic myelogenous leukemia patient]. 38
29415942 2018

Variations for Acute Leukemia of Ambiguous Lineage

ClinVar genetic disease variations for Acute Leukemia of Ambiguous Lineage:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 VHL NM_000551.3(VHL): c.598C> T (p.Arg200Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28940298 3:10191605-10191605 3:10149921-10149921

Expression for Acute Leukemia of Ambiguous Lineage

Search GEO for disease gene expression data for Acute Leukemia of Ambiguous Lineage.

Pathways for Acute Leukemia of Ambiguous Lineage

GO Terms for Acute Leukemia of Ambiguous Lineage

Sources for Acute Leukemia of Ambiguous Lineage

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....